Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on KRAS and Nectin-4, all of which are currently in the pre-clinical stage. This strategic move highlights Lilly’s commitment to advancing cancer therapies that target specific oncogenic pathways.
Details of the New Oncology Programs
The new programs include a KRAS G12D inhibitor designed to selectively target this mutation without affecting wild-type KRAS. Additionally, Lilly is developing an isoform-selective molecule that inhibits multiple oncogenic KRAS mutations while sparing wild-type HRAS and NRAS. Furthermore, the company is working on an antibody-drug conjugate (ADC) that features a topoisomerase I (TOPO 1) inhibitor linked to a Nectin-4-targeting antibody, enhancing the potential for targeted cancer treatment.
Upcoming Data Release and Clinical Plans
Eli Lilly is set to release pre-clinical data on these promising candidates this week. The company aims to advance these programs into clinical trials next year, positioning itself at the forefront of cutting-edge oncology research.-Fineline Info & Tech
